Catalyst Wire Dossier Catalyst Wire Dossier

G12V RAS TCR-T cell therapy

T-cell receptor-engineered T cells targeting G12V-mutated RAS in HLA-A*11:01 · National Cancer Institute
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for G12V RAS TCR-T cell therapy, covering 2026-04-24 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients [Phase 1, Phase 2]

See pricing